Theranica reveals positive study results for migraine device Nerivio
16 July 2020 -

Theranica, a prescribed digital therapeutics company, has revealed positive peer-reviewed study results for its Remote Electrical Neuromodulation (REN) device, Nerivio, intended to treat chronic migraine patients, it was reported on Wednesday.

The study (NCT04161807) used the company's FDA-approved acute migraine treatment device Nerivio and is significant for chronic migraine sufferers who experience around 15 headache days per month. It assessed 38 patients with chronic migraine and assessed REN's efficacy in treating the symptoms of migraine with or without aura.

With Nerivio, 73.7% of participants achieved pain relief at 2 hours and 26.3% were pain free in at least half of their treatments. 84.4% experienced consistent sustained pain relief at 24 hours and 45% had sustained pain relief at 24 hours in at least 50% of their treated attacks. The study thus showed that REN provides consistent response rates from treatment to treatment, with no evidence of reduction in therapeutic benefits over time. Incidence of device-related adverse events was less than 2%.

The product is intended to use REN to activate the body's native Conditioned Pain Modulation mechanism that is intended to treat pain and accompanying migraine symptoms. Nerivio was recently named one of TIME's best inventions of 2019.